Marijuana: Pharmacology and Interaction with the Endocannabinoid System
Substance Abuse and Addictive Disorders
Jenny L. Wiley,
Billy R. Martin,
Jenny L. Wiley
Virginia Commonwealth University, Richmond, Virginia
Search for more papers by this authorBilly R. Martin
Virginia Commonwealth University, Richmond, Virginia
Search for more papers by this authorJenny L. Wiley,
Billy R. Martin,
Jenny L. Wiley
Virginia Commonwealth University, Richmond, Virginia
Search for more papers by this authorBilly R. Martin
Virginia Commonwealth University, Richmond, Virginia
Search for more papers by this authorFirst published: 02 March 2007
Abstract
Marijuana is one of the most widely used illicit psychoactive substances in the U.S. Recently, negative perceptions of marijuana as an abused substance have been tempered somewhat by the idea that it may also have medicinal properties. Regardless of perception of marijuana, however, investigation of its active substituents and their mechanism of action led to the discovery of an endocannabinoid system that is activated by marijuana as well as by several endogenous cannabinoids, including anandamide and 2-arachidonylglycerol. In this chapter, we review the pharmacology of marijuana and discuss how its interaction with the endocannabinoid system may have implications for understanding the physiology of this system.
References
- 1 Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2004). Monitoring the future: National results on adolescent drug use, overview and key findings. (NIH Pub. No. 05-5506). Bethesda, MD: National Institute of Drug Abuse.
- 2 Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., and Stinson, F. S. (2004). Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA 291, 2114–2121.
- 3 Gaoni, Y., and Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647.
- 4 Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., and Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613.
- 5 Compton, D. R., Rice, K. C., De Costa, B. R., Razdan, R. K., Melvin, L. S., Johnson, M. R., and Martin, B. R. (1993). Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265, 218–226.
- 6 Balster, R. L., and Prescott, W. R. (1992). Δ9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biochem. Rev. 16, 55–62.
- 7 Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564.
- 8 Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–64.
- 9 Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949.
- 10 Bisogno, T., Ligresti, A., and Di Marzo, V. (2005). The endocannabinoid signalling system: Biochemical aspects. Pharmacol. Biochem. Behav. 81, 224–238.
- 11 Johnson, M. R., and Melvin, L. S. (1986). The discovery of nonclassical cannabinoid analgetics. In Cannabinoids as Therapeutic Agents, R. Mechoulam, Ed. CRC Press, Boca Raton, FL, pp. 121–144.
- 12 Ward, S. J., Childers, S. R., and Pacheco, M. (1989). Pravadoline and aminoalkylindole (AAI) analogues: Actions which suggest a receptor interaction. Br. J. Pharmacol. 98(Supp.1), 831P.
- 13 Wiley, J. L., and Martin, B. R. (2002). Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids 121, 57–63.
- 14 Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., Ferrara, P., Soubrié, P., Brelière, J. C., and Le Fur, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240–244.
- 15 Rinaldi-Carmona, M., Barth, F., Millan, J., Defrocq, J., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J., and Le Fur, G. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644–650.
- 16 Pertwee, R. G. (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76, 1307–1324.
- 17 Compton, D., Aceto, M., Lowe, J., and Martin, B. (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of Δ9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277, 586–594.
- 18 Bass, C., Griffin, G., Grier, M., Mahadevan, A., Razdan, R., and Martin, B. (2002). SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol. Biochem. Behav. 74, 31.
- 19
Shire, D.,
Carillon, C.,
Kaghad, M.,
Calandra, B.,
Rinaldi-Carmona, M.,
Le Fur, G.,
Caput, D., and
Ferrara, P.
(1995).
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing.
J. Biol. Chem.
270,
3730–3731.
10.1074/jbc.270.8.3726 Google Scholar
- 20 Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., Marnett, L. J., Di Marzo, V., Pittman, Q. J., Patel, K. D., and Sharkey, K. A. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329–332.
- 21 Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Boulaboula, M., Shire, D., Le Fur, G., and Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54–61.
- 22 Kaminski, N. E. (1996). Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem. Pharmacol. 52, 1133–1140.
- 23 Showalter, V., Compton, D. R., Martin, B. R., and Abood, M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989–999.
- 24 Begg, M., Pacher, P., Batkai, S., Osei-Hyiaman, D., Offertaler, L., Mo, F. M., Liu, J., and Kunos, G. (2005). Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106, 133–145.
- 25 Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., DeCosta, B. R., and Rice, K. C. (1990). Cannabinoid receptor localization in the brain. Proc. Natl. Acad. Sci. USA 87, 1932–1936.
- 26 Prather, P. L., Martin, N. A., Breivogel, C. S., and Childers, S. R. (2000). Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol. Pharmacol. 57, 1000–1010.
- 27 Glass, M., and Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 5327–5333.
- 28 Mackie, K., and Hille, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 89, 3825–3829.
- 29 Mackie, K., Lai, Y., Westenbroek, R., and Mitchell, R. (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15, 6552–6561.
- 30 Bouaboula, M., Bourrié, B., Rinaldi-Carmona, M., Shire, D., Le Fur, G., and Casellas, P. (1995). Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270, 13973–13980.
- 31 Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., Westwood, P., Marrs, J., Thomson, F., Cowley, P., Christopoulos, A., Pertwee, R. G., and Ross, R. A. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68, 1484–1495.
- 32 Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161–202.
- 33 Wilson, R. I., and Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588–592.
- 34 Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N., Schatz, A., Gopher, A., Almog, S., Martin, B., Compton, D., Pertwee, R., Griffin, G., Bayewitch, M., Barg, J., and Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90.
- 35 Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., and Mechoulam, R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662–3665.
- 36 Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., Miller, J. D., Davies, S. N., Geppetti, P., Walker, J. M., and Di Marzo, V. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA 99, 8400–8405.
- 37 Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., and Felder, C. C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020–1024.
- 38 Howlett, A. C., and Mukhopadhyay, S. (2000). Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108, 53–70.
- 39 Smart, D., and Jerman, J. C. (2000). Anandamide: An endogenous activator of the vanilloid receptor [letter; comment]. Trends Pharmacol. Sci. 21, 134.
- 40 Zygmunt, P. M., Peterson, J., Andersson, D. A., Chuang, H. H., Sorgard, M., DiMarzo, V., and Julius, D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452–457.
- 41 Schmid, H. H. (2000). Pathways and mechanisms of N-acylethanolamine biosynthesis: Can anandamide be generated selectively? Chem. Phys. Lipids 108, 71–87.
- 42 Cravatt, B. F., and Lichtman, A. H. (2002). The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem. Phys. Lipids 121, 135–148.
- 43 Patricelli, M. P., Patterson, J. E., Boger, D. L., and Cravatt, B. F. (1998). An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett. 8, 613–618.
- 44 Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., and Lichtman, A. H. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98, 9371–9376.
- 45 Hillard, C. J., and Jarrahian, A. (2000). The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids 108, 123–134.
- 46 Fried, P. A. (2002). Adolescents prenatally exposed to marijuana: Examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. J. Clin. Pharmacol. 42, 97S–102S.
- 47 Abel, E. L. (1984). Effects of delta 9-THC on pregnancy and offspring in rats. Neurobehav. Toxicol. Teratol. 6, 29–32.
- 48 Belue, R., Howlett, A., Westlake, T., and Hutchings, D. (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol. Teratol. 17, 25–30.
- 49 McLaughlin, C. R., Martin, B. R., Compton, D. R., and Abood, M. E. (1994). Cannabinoid receptors in developing rats: Detection of mRNA and receptor binding. Drug Alcohol Depend. 36, 27–31.
- 50 Rodriguez de Fonseca, F., Ramos, J. A., Bonnin, A., and Fernandez, R. J. J. (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4, 135–138.
- 51
Berrendero, F.,
Sepe, N.,
Ramos, J. A.,
Di Marzo, V., and
Fernandez-Ruiz, J. J.
(1999).
Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period.
Synapse
33,
181–191.
10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 52 Berrendero, F., Garcia-Gil, L., Hernandez, M. L., Romero, J., Cebeira, M., de Miguel, R., Ramos, J. A., and Fernandez-Ruiz, J. J. (1998). Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 125, 3179–3188.
- 53
Romero, J.,
Garcia-Palomero, E.,
Berrendero, F.,
Garcia-Gil, L.,
Hernandez, M. L.,
Ramos, J. A., and
Fernandez-Ruiz, J. J.
(1997).
Atypical location of cannabinoid receptors in white matter areas during rat brain development.
Synapse
26,
317–323.
10.1002/(SICI)1098-2396(199707)26:3<317::AID-SYN12>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 54 Fride, E., Ginzburg, Y., Breuer, A., Bisogno, T., Di Marzo, V., and Mechoulam, R. (2001). Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur. J. Pharmacol. 419, 207–214.
- 55 de Graff-Peters, V. B., and Hadders-Algra, M. (2006). Ontogeny of the human central nervous system: What is happening when? Early Hum. Dev. 82, 257–266.
- 56 Martin, B. R. (1995). Marijuana. In Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom, Eds. Raven, New York, pp. 1757–1765.
- 57 Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R., and Ward, S. J. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40, 471–478.
- 58 Wiley, J. L. (1999). Cannabis: Discrimination of “internal bliss”? Pharmacol. Biochem. Behav. 64, 257–260.
- 59 Wiley, J., Lowe, J., Balster, R., and Martin, B. (1995). Antagonism of the discriminative stimulus effects of Δ9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275, 1–6.
- 60 Wiley, J. L., Jefferson, R. G., Griffin, G., Liddle, J., Yu, S., Huffman, J. W., and Martin, B. R. (2002). Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB(1) receptor Affinity. Pharmacology 66, 89–99.
- 61 Ryan, J. W., Banner, W. K., Wiley, J. L., Martin, B. R., and Razdan, R. K. (1997). Potent anandamide analogs: The effect of changing the length and branching of the end pentyl chain. J. Med. Chem. 40, 3617–3625.
- 62 Seltzman, H. H., Fleming, D. N., Thomas, B. F., Gilliam, A. F., McCallion, D. S., Pertwee, R. G., Compton, D. R., and Martin, B. R. (1997). Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J. Med. Chem. 40, 3626–3634.
- 63 Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R., and Martin, B. R. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270, 219–227.
- 64 Adams, I. B., Ryan, W., Singer, M., Thomas, B. F., Compton, D. R., Razdan, R. K., and Martin, B. R. (1995). Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273, 1172–1181.
- 65 Adams, I. B., Ryan, W., Singer, M., Razdan, R. K., Compton, D. R., and Martin, B. R. (1995). Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56, 2041–2048.
- 66 Wiley, J. L., Golden, K. M., Ryan, W. J., Balster, R. L., Razdan, R. K., and Martin, B. R. (1997). Discriminative stimulus effects of anandamide and methylated fluoroanandamide in Δ9-THC-trained rhesus monkeys. Pharmacol. Biochem. Behav. 58, 1139–1143.
- 67 Houser, S. J., Eads, M., Embrey, J. P., and Welch, S. P. (2000). Dynorphin B and spinal analgesia: Induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res. 857, 337–342.
- 68 Welch, S. P., and Eads, M. (1999). Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848, 183–190.
- 69 Adams, I. B., Compton, D. R., and Martin, B. R. (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284, 1209–1217.
- 70 Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87.
- 71 Willoughby, K. A., Moore, S. F., Martin, B. R., and Ellis, E. F. (1997). The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282, 243–247.
- 72 Watanabe, K., Narimatsu, S., Matsunaga, T., Yamamoto, I., and Yoshimura, H. (1993). A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes. Biochem. Pharmacol. 46, 405–411.
- 73 Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313, 352–358.
- 74 Compton, D. R., and Martin, B. R. (1997). The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Ther. 283, 1138–1143.
- 75 Noyes, J. R., Brunk, S. F., Avery, D. H., and Canter, A. (1975). The analgesic properties of Δ9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18, 84–89.
- 76 Noyes, R., Jr., Brunk, S. F., Baram, D. A., and Canter, A. (1975). Analgesic effect of Δ9-tetrahydrocannabinol. J. Clin. Pharmacol. 15, 139–143.
- 77 Karniol, I. G., Shirakawa, I., Takahashi, R. N., Knobel, E., and Musty, R. E. (1975). Effects of Δ9-tetrahydrocannabinol and cannabinol in man. Pharmacology 13, 502–512.
- 78 Raft, D., Gregg, J., Ghia, J., and Harris, L. (1977). Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21, 26–33.
- 79
Jain, A. K.,
Ryan, J. E.,
McMahan, F. G., and
Smith, G.
(1981).
Evaluation of intra-muscular levonantradol in acute post-operative pain.
J. Clin. Pharmacol.
21,
3205–3265.
10.1002/j.1552-4604.1981.tb02610.x Google Scholar
- 80 Jochimsen, P. R., Lawton, R. L., VerSteeg, K., and Noyes, J. R. (1978). Effect of benzopyranoperidine, a Δ-9-THC congener, on pain. Clin. Pharmacol. Ther. 24, 223–227.
- 81 Martin, B. R., and Lichtman, A. H. (1998). Cannabinoid transmission and pain perception. Neurobiol. Dis. 5, 447–461.
- 82 Walker, J. M., Hohmann, A. G., Martin, W. J., Strangman, N. M., Huang, S. M., and Tsou, K. (1999). The neurobiology of cannabinoid analgesia. Life Sci. 65, 665–673.
- 83 Lichtman, A. H., and Martin, B. R. (1991). Cannabinoid induced antinociception is mediated by a spinal α2 noradrenergic mechanism. Brain Res. 559, 309–314.
- 84 Smith, P. B., Welch, S. P., and Martin, B. R. (1993). nor-Binaltorphimine specifically inhibits Δ9-tetrahydrocannabinol-induced antinociception in mice without altering other pharmacological effects. J. Pharmacol. Exp. Ther. 268, 1381–1387.
- 85 Gough, A. L., and Olley, J. E. (1978). Catalepsy induced by intrastriatal injections of Δ9-THC and 11-OH-Δ9-THC in the rat. Neuropharmacology 17, 137–144.
- 86 Lichtman, A. H., Cook, S. A., and Martin, B. R. (1996). Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276, 585–593.
- 87 Herzberg, U., Eliav, E., Bennett, G. J., and Kopin, I. J. (1997). The analgesic effects of R (+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurol. Lett. 221, 157–160.
- 88 Smith, F. L., Fujimori, K., Lowe, J., and Welch, S. P. (1998). Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 60, 183–191.
- 89 Fride, E., and Mechoulam, R. (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231, 313–314.
- 90 Stein, E. A., Fuller, S. A., Edgemond, W. S., and Campbell, W. B. (1996). Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br. J. Pharmacol. 119, 107–114.
- 91 Martin, W. J., Patrick, S. L., Coffin, P. O., Tsou, K., and Walker, J. M. (1995). An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56, 2103–2109.
- 92 Basbaum, A. I., and Fields, H. L. (1984). Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7, 309–338.
- 93 Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583.
- 94 Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K., and Sanudo-Pena, M. C. (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA 96, 12198–12203.
- 95 Meng, I. D., Manning, B. H., Martin, W. J., and Fields, H. L. (1998). An analgesia circuit activated by cannabinoids. Nature 395, 381–383.
- 96 Calignano, A., La Rana, G., Giuffrida, A., and Piomelli, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature 394, 277–281.
- 97 Beaulieu, P., Bisogno, T., Punwar, S., Farquhar-Smith, W. P., Ambrosino, G., Di Marzo, V., and Rice, A. S. (2000). Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur. J. Pharmacol. 396, 85–92.
- 98 Suplita, R. L., II, Farthing, J. N., Gutierrez, T., and Hohmann, A. G. (2005). Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: Sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 49, 1201–1209.
- 99 Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Walker, J. M., Holmes, P. V., Crystal, J. D., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108–1112.
- 100 Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2004). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311, 441–448.
- 101 Richardson, J. D., Aanonsen, L., and Hargreaves, K. M. (1998). Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18, 451–457.
- 102 Hohmann, A. G., Martin, W. J., Tsou, K., and Walker, J. M. (1995). Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56, 2111–2118.
- 103 Martin, W. J., Hohmann, A. G., and Walker, J. M. (1996). Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16, 6601–6611.
- 104 Lichtman, A. H., and Martin, B. R. (1991). Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258, 517–523.
- 105 Martin, W. J., Lai, N. K., Patrick, S. L., Tsou, K., and Walker, J. M. (1993). Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629, 300–304.
- 106 Jacob, J. J., Ramabadran, K., and Campos-Medeiros, M. (1981). A pharmacological analysis of levonantradol antinociception in mice. J. Clin. Pharmacol. 21, 327S–333S.
- 107 Ferri, S., Cavicchini, E., Romualdi, P., Speroni, E., and Murari, G. (1986). Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology 89, 244–247.
- 108 Naderi, N., Shafaghi, B., Khodayar, M. J., and Zarindast, M. R. (2005). Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat. Eur. J. Pharmacol. 514, 159–164.
- 109 Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., and Fride, E. (1999). HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA 96, 14228–14233.
- 110 Quartilho, A., Mata, H. P., Ibrahim, M. M., Vanderah, T. W., Porreca, F., Makriyannis, A., and Malan, T. P., Jr. (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99, 955–960.
- 111 Scott, D. A., Wright, C. E., and Angus, J. A. (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109, 124–131.
- 112 Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., Rabadi, L., Rotshteyn, Y., Chaffer, S. M., Turchin, P. I., Elsemore, D. A., Toth, M., Koetzner, L., and Whiteside, G. T. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48, 658–672.
- 113 Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., and Winter, J. (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135, 235–245.
- 114 Jerman, J. C., Gray, J., Brough, S. J., Ooi, L., Owen, D., Davis, J. B., and Smart, D. (2002). Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. Br. J. Anaesth. 89, 882–887.
- 115 Lam, P. M., McDonald, J., and Lambert, D. G. (2005). Characterization and comparison of recombinant human and rat TRPV1 receptors: Effects of exo- and endocannabinoids. Br. J. Anaesth. 94, 649–656.
- 116 Di Marzo, V., Griffin, G., De Petrocellis, L., Brandi, I., Bisogno, T., Williams, W., Grier, M. C., Kulasegram, S., Mahadevan, A., Razdan, R. K., and Martin, B. R. (2002). A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300, 984–991.
- 117 Curran, H. V., Brignell, C., Fletcher, S., Middleton, P., and Henry, J. (2002). Cognitive and subjective dose-response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164, 61–70.
- 118 Kurzthaler, I., Hummer, M., Miller, C., Sperner-Unterweger, B., Gunther, V., Wechdorn, H., Battista, H. J., and Fleischhacker, W. W. (1999). Effect of cannabis use on cognitive functions and driving ability. J. Clin. Psychiatry 60, 395–399.
- 119 Pope, H. G., Jr., Gruber, A. J., Hudson, J. I., Huestis, M. A., and Yurgelun-Todd, D. (2001). Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry 58, 909–915.
- 120 Hicks, R. E., Gualtieri, C. T., Mayo, J. P., Jr., and Perez-Reyes, M. (1984). Cannabis, atropine, and temporal information processing. Neuropsychobiology 12, 229–237.
- 121 Vachon, L., Sulkowski, A., and Rich, E. (1974). Marihuana effects on learning, attention and time estimation. Psychopharmacologia 39, 1–11.
- 122 Castellano, C., Rossi-Arnaud, C., Cestari, V., and Costanzi, M. (2003). Cannabinoids and memory: Animal studies. Curr. Drug. Targets CNS Neurol. Disord. 2, 389–402.
- 123 Hampson, R. E., and Deadwyler, S. A. (1998). Role of cannabinoid receptors in memory storage. Neurobiol. Dis. 5, 474–482.
- 124 Heyser, C. J., Hampson, R. E., and Deadwyler, S. A. (1993). Effects of Δ9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264, 294–307.
- 125 Lichtman, A. H., and Martin, B. R. (1996). Δ9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126, 125–131.
- 126 Lichtman, A. H., Dimen, K. R., and Martin, B. R. (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119, 282–290.
- 127 Varvel, S. A., and Lichtman, A. H. (2002). Evaluation of CB1 receptor knockout mice in the Morris water maze. J. Pharmacol. Exp. Ther. 301, 915–924.
- 128 Jentsch, J., Andrusiak, E., Tran, A., Bowers, M., and Roth, R. (1997). Δ9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: Blockade of dopaminergic effects with HA966. Neuropsychopharmacology 16, 426–432.
- 129 Delatte, M. S., Winsauer, P. J., and Moerschbaecher, J. M. (2002). Tolerance to the disruptive effects of delta(9)-THC on learning in rats. Pharmacol. Biochem. Behav. 74, 129–140.
- 130 Miller, L. L., McFarland, D. J., Cornett, T. L., Brightwell, D. R., and Wikler, A. (1977). Marijuana: Effects on free recall and subjective organization of pictures and words. Psychopharmacology 55, 257–262.
- 131 McClure, G. Y., and McMillan, D. E. (1997). Effects of drugs on response duration differentiation. VI: Differential effects under differential reinforcement of low rates of responding schedules. J. Pharmacol. Exp. Ther. 281, 1368–1380.
- 132 Wiley, J. L., Compton, A. D., and Golden, K. M. (2000). Separation of drug effects on timing and behavioral inhibition by increased stimulus control. Exp. Clin. Psychopharmacol. 8, 451–461.
- 133 Han, C. J., and Robinson, J. K. (2001). Cannabinoid modulation of time estimation in the rat. Behav. Neurosci. 115, 243–246.
- 134 Varvel, S. A., Bridgen, D. T., Tao, Q., Thomas, B. F., Martin, B. R., and Lichtman, A. H. (2005). Delta9-tetrahydrocannabinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J. Pharmacol. Exp. Ther. 314, 329–337.
- 135 Beal, J. E., Olson, R., Laubenstein, L., MOrales, J. O., Bellman, B., Yangco, B., Lefkowitz, L., Plasse, T. F., and Shepard, K. V. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manag. 10, 89–97.
- 136 Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., Pundaleeka, S., Kardinal, C. G., Fitch, T. R., Krook, J. E., Novotny, P. J., and Christensen, B. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J. Clin. Oncol. 20, 567–573.
- 137 Avraham, Y., Ben-Shushan, D., Breuer, A., Zolotarev, O., Okon, A., Fink, N., Katz, V., and Berry, E. M. (2004). Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacol. Biochem. Behav. 77, 675–684.
- 138 Williams, C. M., and Kirkham, T. C. (2002). Observational analysis of feeding induced by delta9-THC and anandamide. Physiol. Behav. 76, 241–250.
- 139 Williams, C. M., Rogers, P. J., and Kirkham, T. C. (1998). Hyperphagia in pre-fed rats following oral delta9-THC. Physiol. Behav. 65, 343–346.
- 140 Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., and Kunos, G. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822–825.
- 141 Wiley, J. L., Burston, J. J., Leggett, D. C., Alekseeva, O. O., Razdan, R. K., Mahadevan, A., and Martin, B. R. (2005). CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 145, 293–300.
- 142 Williams, C. M., and Kirkham, T. C. (1999). Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143, 315–317.
- 143 McLaughlin, P. J., Winston, K., Swezey, L., Wisniecki, A., Aberman, J., Tardif, D. J., Betz, A. J., Ishiwari, K., Makriyannis, A., and Salamone, J. D. (2003). The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav. Pharmacol. 14, 583–588.
- 144 Rowland, N. E., Mukherjee, M., and Robertson, K. (2001). Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159, 111–116.
- 145 Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., and Rossner, S. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389–1397.
- 146 Harrold, J. A., and Williams, G. (2003). The cannabinoid system: A role in both the homeostatic and hedonic control of eating?. Br. J. Nutr. 90, 729–734.
- 147 Kirkham, T. C., Williams, C. M., Fezza, F., and Di Marzo, V. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136, 550–557.
- 148 Jamshidi, N., and Taylor, D. A. (2001). Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134, 1151–1154.
- 149 Chiesi, M., Huppertz, C., and Hofbauer, K. G. (2001). Pharmacotherapy of obesity: Targets and perspectives. Trends Pharmacol. Sci. 22, 247–254.
- 150 Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thone-Reineke, C., Ortmann, S., Tomassoni, F., Cervino, C., Nisoli, E., Linthorst, A. C., Pasquali, R., Lutz, B., Stalla, G. K., and Pagotto, U. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423–431.
- 151 Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., and Soubrie, P. (2003). The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908–914.
- 152 Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes, E., Peleraux, A., Penarier, G., Soubrie, P., Le Fur, G., Galiegue, S., and Casellas, P. (2005). The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19, 1567–1569.
- 153 Hanus, L., Avraham, Y., Ben-Shushan, D., Zolotarev, O., Berry, E. M., and Mechoulam, R. (2003). Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res. 983, 144–151.
- 154 Harrold, J. A., Elliott, J. C., King, P. J., Widdowson, P. S., and Williams, G. (2002). Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: A role for endogenous cannabinoids in driving appetite for palatable food? Brain Res. 952, 232–238.
- 155 Karler, R., Calder, L. D., Sangdee, P., and Turkanis, S. A. (1984). Interaction between Δ9-tetrahydrocannabinol and kindling by electrical and chemical stimuli in mice. Neuropharmacology 23, 1315–1320.
- 156 Karler, R., Cely, W., and Turkanis, S. A. (1974). A study of the relative anticonvulsant and toxic activities of Δ9-tetrahydrocannabinol and its congeners. Res. Comm. Chem. Path. Pharm. 7, 353–358.
- 157 Karler, R., Cely, W., and Turkanis, S. A. (1973). The anticonvulsant activity of cannabidiol and cannabinol. Life Sci. 13, 1527–1531.
- 158 Wallace, M. J., Wiley, J. L., Martin, B. R., and DeLorenzo, R. J. (2001). Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428, 51–57.
- 159 Wallace, M., Martin, B., and DeLorenzo, R. (2002). Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 452, 295.
- 160 Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., and DeLorenzo, R. J. (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 307, 129–137.
- 161 Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutierrez, S. O., van der Stelt, M., Lopez-Rodriguez, M. L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo, V., Behl, C., and Lutz, B. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84–88.
- 162 Lutz, B. (2004). On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 68, 1691–1698.
- 163 Clement, A. B., Hawkins, E. G., Lichtman, A. H., and Cravatt, B. F. (2003). Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916–3923.
- 164 Quistad, G. B., Sparks, S. E., Segall, Y., Nomura, D. K., and Casida, J. E. (2002). Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: Toxicological implications. Toxicol. Appl. Pharmacol. 179, 57–63.
- 165 Shen, M., and Thayer, S. A. (1999). Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol. Pharmacol. 55, 8–13.
- 166 Ameri, A., Wilhelm, A., and Simmet, T. (1999). Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br. J. Pharmacol. 126, 1831–1839.
- 167 Chen, K., Ratzliff, A., Hilgenberg, L., Gulyas, A., Freund, T. F., Smith, M., Dinh, T. P., Piomelli, D., Mackie, K., and Soltesz, I. (2003). Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 39, 599–611.
- 168 Wilson, R. I., and Nicoll, R. A. (2002). Endocannabinoid signaling in the brain. Science 296, 678–682.
- 169 Chan, G. C., Hinds, T. R., Impey, S., and Storm, D. R. (1998). Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J. Neurosci. 18, 5322–5332.
- 170 Downer, E. J., Fogarty, M. P., and Campbell, V. A. (2003). Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br. J. Pharmacol. 140, 547–557.
- 171 Milton, N. G. (2002). Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 332, 127–130.
- 172 Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., and Behl, C. (2002). Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J. Neurochem. 80, 448–456.
- 173 Hamelink, C., Hampson, A., Wink, D. A., Eiden, L. E., and Eskay, R. L. (2005). Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J. Pharmacol. Exp. Ther. 314, 780–788.
- 174 Hampson, A. J., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268–8273.
- 175 Darmani, N. A. (2001). Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198–203.
- 176 Parker, L. A., Kwiatkowska, M., Burton, P., and Mechoulam, R. (2004). Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171, 156–161.
- 177 Kwiatkowska, M., Parker, L. A., Burton, P., and Mechoulam, R. (2004). A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174, 254–259.
- 178 Parker, L. A., and Kemp, S. W. (2001). Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: An animal model of anticipatory nausea and vomiting (ANV). Neuroreport 12, 749–751.
- 179 Parker, L. A., and Mechoulam, R. (2003). Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr. Physiol. Behav. Sci. 38, 133–145.
- 180 Simoneau, I. I., Hamza, M. S., Mata, H. P., Siegel, E. M., Vanderah, T. W., Porreca, F., Makriyannis, A., and Malan, T. P., Jr. (2001). The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94, 882–887.
- 181 Darmani, N. A., Sim-Selley, L. J., Martin, B. R., Janoyan, J. J., Crim, J. L., Parekh, B., and Breivogel, C. S. (2003). Antiemetic and motor-depressive actions of CP55,940: Cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur. J. Pharmacol. 459, 83–95.
- 182 Van Sickle, M. D., Oland, L. D., Ho, W., Hillard, C. J., Mackie, K., Davison, J. S., and Sharkey, K. A. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121, 767–774.
- 183 Van Sickle, M. D., Oland, L. D., Mackie, K., Davison, J. S., and Sharkey, K. A. (2003). Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G566–G576.
- 184 Darmani, N. A., and Johnson, J. C. (2004). Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur. J. Pharmacol. 488, 201–212.
- 185 Darmani, N. A., and Crim, J. L. (2005). Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav. 80, 35–44.
- 186 McCabe, M., Smith, F. P., Macdonald, J. S., Woolley, P. V., Goldberg, D., and Schein, P. S. (1988). Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest. New Drugs 6, 243–246.
- 187 Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., and Wadleigh, R. G. (1991). Recent clinical experience with Dronabinol. Pharmacol. Biochem. Behav. 40, 695–700.
- 188 Lane, M., Vogel, C. L., Ferguson, J., Krasnow, S., Saiers, J. L., Hamm, J., Salva, K., Wiernik, P. H., Holroyde, C. P., Hammill, S., et al. 1991). Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J. Pain Symptom Manag. 6, 352–359.
- 189 Ahmedzai, S., Carlyle, D. L., Calder, I. T., and Moran, F. (1983). Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br. J. Cancer 48, 657–663.
- 190 Abrahamov, A., and Mechoulam, R. (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 56, 2097–2102.
- 191 Chan, H. S., Correia, J. A., and MacLeod, S. M. (1987). Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics 79, 946–952.
- 192 Fattore, L., Cossu, G., Martellotta, C. M., and Fratta, W. (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl.) 156, 410–416.
- 193 Justinova, Z., Tanda, G., Redhi, G. H., and Goldberg, S. R. (2003). Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 169, 135–140.
- 194 Tanda, G., Munzar, P., and Goldberg, S. R. (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 3, 1073–1074.
- 195 Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., and Frank, R. A. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322–328.
- 196 Justinova, Z., Goldberg, S. R., Heishman, S. J., and Tanda, G. (2005). Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol. Biochem. Behav. 81, 285–299.
- 197 Lupica, C. R., Riegel, A. C., and Hoffman, A. F. (2004). Marijuana and cannabinoid regulation of brain reward circuits. Br. J. Pharmacol. 143, 227–234.
- 198 Chen, J., Paredes, W., Li, J., Smith, D., Lowinson, J., and Gardner, E. (1990). Δ9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely moving rats as measured by intracerebral microdialysis. Psychopharmacology 102, 156–162.
- 199 Chen, J., Paredes, W., Lowinson, J. H., and Gardner, E. L. (1990). Δ9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur. J. Pharmacol. 190, 259–262.
- 200 Diana, M., Melis, M., and Gessa, G. L. (1998). Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur. J. Neurosci. 10, 2825–2830.
- 201 French, E. D., Dillon, K., and Wu, X. (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8, 649–652.
- 202 Cheer, J. F., Marsden, C. A., Kendall, D. A., and Mason, R. (2000). Lack of response suppression follows repeated ventral tegmental cannabinoid administration: An in vitro electrophysiological study. Neuroscience 99, 661–667.
- 203 Szabo, B., Siemes, S., and Wallmichrath, I. (2002). Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neurosci. 15, 2057–2061.
- 204 Tanda, G., Pontieri, F., and Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science 276, 2048–2050.
- 205 Melis, M., Pistis, M., Perra, S., Muntoni, A. L., Pillolla, G., and Gessa, G. L. (2004). Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 24, 53–62.
- 206 Compton, D. R., Dewey, W. L., and Martin, B. R. (1990). Cannabis dependence and tolerance production. In Addiction Potential of Abused Drugs and Drug Classes, C. K. Erickson, M. A. Javors, and W. W. Morgan, Eds. Hayworth, Binghampton, NY, pp. 129–147.
- 207 Lamb, R. J., Jarbe, T. U., Makriyannis, A., Lin, S., and Goutopoulos, A. (2000). Effects of delta9-tetrahydrocannabinol, (R)-methanandamide, SR 141716, and d-amphetamine before and during daily delta9-tetrahydrocannabinol dosing. Eur. J. Pharmacol. 398, 251–258.
- 208 Welch, S. P., Dunlow, L. D., Patrick, G. S., and Razdan, R. K. (1995). Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to Δ9-THC following intrathecal administration to mice: Blockade of Δ9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273, 1235–1244.
- 209 Wiley, J. L., Smith, F. L., Razdan, R. K., and Dewey, W. L. (2005). Task specificity of cross-tolerance between delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur. J. Pharmacol. 510, 59–68.
- 210 Breivogel, C. S., Scates, S. M., Beletskaya, I. O., Lowery, O. B., Aceto, M. D., and Martin, B. R. (2003). The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur. J. Pharmacol. 459, 139–150.
- 211 Sim-Selley, L. J., and Martin, B. R. (2002). Effect of chronic administration of R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylae (WIN55,212-2) or Δ9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J. Pharmacol. Exp. Ther. 303, 36–44.
- 212 Aceto, M. D., Scates, S. M., and Martin, B. B. (2001). Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur. J. Pharmacol. 416, 75–81.
- 213 Aceto, M., Scates, S., Lowe, J., and Martin, B. (1996). Dependence on Δ9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J. Pharmacol. Exp. Ther. 278, 1290–1295.
- 214 Tsou, K., Patrick, S., and Walker, J. M. (1995). Physical withdrawal in rats tolerant to Δ9-tetrahydrocannabinol precipated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280, R13–R15.
- 215 Hutcheson, D. M., Tzavara, E. T., Smadja, C., Valjent, E., Roques, B. P., Hanoune, J., and Maldonado, R. (1998). Behavioral and biochemical evidence for signs of abstinence in mice chemically treated with Δ9-terahydrocannabinol. J. Pharmacol. 125, 1567–1577.
- 216 Lichtman, A. H., Fisher, J., and Martin, B. R. (2001). Precipitated cannabinoid withdrawal is reversed by delta(9)-tetrahydrocannabinol or clonidine. Pharmacol. Biochem. Behav. 69, 181–188.
- 217 Budney, A. J., and Moore, B. A. (2002). Development and consequences of cannabis dependence. J. Clin. Pharmacol. 42, 28S–33S.
